What is Xcovery?
Xcovery is dedicated to advancing oncology therapies through cutting-edge science, aiming to develop treatments that are not only more effective but also less toxic and more tolerable for patients. The company's mission is to expedite the transition of life-changing cancer agents from research to clinical application, thereby enhancing the quality of life for individuals courageously battling cancer and empowering the oncology community to provide better patient outcomes. The company's strategic focus on innovative oncology solutions positions it within a critical segment of the biopharmaceutical industry, driven by unmet medical needs.
How much funding has Xcovery raised?
Xcovery has raised a total of $48.9M across 8 funding rounds:
Series A
$2.4M
Series B
$6M
Debt
$2.1M
Multiple Rounds
$38.1M
Debt
$350K
Series A (2011): $2.4M, investors not publicly disclosed
Series B (2012): $6M, investors not publicly disclosed
Debt (2013): $2.1M, investors not publicly disclosed
Series C (2014): $2.4M, investors not publicly disclosed
Series D (2014): $15M backed by EMS S/A and Brace Pharma
Debt (2014): $675K, investors not publicly disclosed
Private Equity (2014): $20M led by Betta Pharmaceuticals
Debt (2020): $350K supported by PPP
Key Investors in Xcovery
Betta Pharmaceuticals
Betta Pharmaceuticals Co., Ltd. is a leading Chinese pharmaceutical company focused on developing and commercializing innovative oncology products. They have a strong track record in small-molecule and biologics discovery and development, with a notable product for non-small cell lung cancer.
EMS S/A
EMS Pharma is a prominent Brazilian pharmaceutical company founded in 1950, engaged in the distribution of pharmaceutical products within Brazil.
Brace Pharma
Brace Pharma Capital is an investment firm that concentrates on innovative therapies for diseases with significant unmet medical needs, aiming to support the development of life-changing medicines.
What's next for Xcovery?
With substantial enterprise-level backing and a recent strategic investment, Xcovery is poised for accelerated growth and development in its oncology pipeline. The company's trajectory, marked by a series of funding rounds including Series A, B, C, and D, as well as private equity and debt financing, indicates a robust financial strategy supporting its long-term vision. Future endeavors will likely focus on advancing its lead therapeutic candidates through clinical trials, expanding its research and development capabilities, and potentially forging strategic partnerships to broaden market access and impact. The company's commitment to creating less toxic and more effective cancer treatments suggests a continued emphasis on innovation and patient-centric solutions.
See full Xcovery company page
